#52 – A Conversation with the Authors of IDSA Guidance on Treatment of AmpC, CRAB, and Stenotrophomonas

Drs. Pranita Tamma (@pranita_tamma) and Sam Aitken (@OncIDPharmd) are BACK on the podcast this week with Dr. Erin McCreary (@ErinMcCreary) to discuss IDSA guidance on AmpC producers, carbapenem-resistant Acinetobacter baumanii, and Stenotrophomonas as part of our series on gram-negative bacteria. Listen as the panelists navigate the hot mess that is the CRAB treatment landscape, have a minocycline appreciation moment (we stan for Steno Sam!), and throw down some bar trivia in an “I Feel Nerdy” segment that you don’t want to miss.
 
Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/
 
References
  1. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa) – PubMed (nih.gov)
  2. Infectious Diseases Society of America Guidance on the Treatment of AmpC β-lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections – PubMed (nih.gov)
  3. An Overview of the Treatment of Less Common Non-Lactose-Fermenting Gram-Negative Bacteria
  4. Alterations of the Oral Microbiome and Cumulative Carbapenem Exposure Are Associated With Stenotrophomonas maltophilia Infection in Patients With Acute Myeloid Leukemia Receiving Chemotherapy

Pranita Tamma, MD, MHS

Dr. Pranita Tamma is an associate professor of Pediatrics in the division of infectious diseases and the director of the Pediatric antimicrobial stewardship program at The John Hopkins University School of Medicine. Her research focuses on improving the understanding of gram-negative bacterial resistance, improving available diagnostics to identify gram-negative resistant pathogens, and optimizing therapeutic choices for infections caused by drug resistant gram negative organisms. She currently has research funding from the NIH, the FDA, the CDC, and AHRQ to investigate these areas.  

Sam Aitken PharmD, MPH, BCIDP

Dr. Sam Aitken is a clinical pharmacy specialist in infectious diseases at the University of Michigan and an adjunct clinical professor of pharmacy at Michigan’s College of Pharmacy. He completed a PGY1 pharmacy residency at Yale-New Haven Hospital and then an infectious diseases fellowship at the University of Houston. He previously served as an ID pharmacist at MD Anderson Cancer Center where he became one of the world’s leading experts in immunocompromised infectious diseases. He has experience in treating resistant pathogens in complex hosts, has made a career in leveraging pharmacokinetic and pharmacodynamic knowledge, and utilization of the interplay of antibiotic bug post dynamics in order to optimize patient care.

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Podcasts

Join the Conversation: Subscribe to Our Podcast for Exclusive Insights!

Subscribe

Founded in 1990, the Society of Infectious Diseases Pharmacists (SIDP) is dedicated to promoting the appropriate use of antimicrobials through education, training, research, and policy. 

PO Box 1488
Warrenville, IL 60555
(331) 248-7888
sidp@affinity-strategies.com

Site Links

Listen

SIDP Logo

© 2024 Society of Infectious Diseases Pharmacists / PO Box 1488, Warrenville, IL 60555
(331) 248-7888 / sidp@affinity-strategies.com

Instagram Twitter Facebook Youtube Linkedin